Get the Stockscreener App
5.41
4.56%
0.26
Savara Inc stock is traded at $5.41, with a volume of 1.19M.
It is up +4.56% in the last 24 hours and up +23.51% over the past month.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
See More
Previous Close:
$5.15
Open:
$5.16
24h Volume:
1.19M
Relative Volume:
0.74
Market Cap:
$1.10B
Revenue:
-
Net Income/Loss:
$-54.70M
P/E Ratio:
-16.39
EPS:
-0.33
Net Cash Flow:
$-51.36M
1W Performance:
+17.07%
1M Performance:
+23.51%
6M Performance:
+89.61%
1Y Performance:
+55.64%
1-Day Range:
$5.09
$5.485
1-Week Range:
$4.59
$5.485
52-Week Range:
$1.89
$5.485
Savara Inc Stock (SVRA) Company Profile
Name
Savara Inc
Sector
Industry
Phone
51285113796
Address
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
5.405 | 1.05B | 0 | -54.70M | -51.36M | -0.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
430.98 | 109.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
786.75 | 82.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
443.28 | 56.78B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
919.57 | 56.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.06 | 44.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Nov-13-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-24 | Initiated | JMP Securities | Mkt Outperform |
| Nov-07-23 | Initiated | Guggenheim | Buy |
| May-16-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-31-23 | Downgrade | Jefferies | Buy → Hold |
| Mar-16-21 | Initiated | Piper Sandler | Overweight |
| Mar-15-21 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-13-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-13-19 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-13-18 | Resumed | ROTH Capital | Neutral |
| Jan-03-18 | Initiated | Ladenburg Thalmann | Buy |
| Sep-27-17 | Resumed | ROTH Capital | Buy |
| Sep-22-17 | Initiated | Jefferies | Buy |
| Sep-11-17 | Initiated | JMP Securities | Mkt Outperform |
View All
Savara Inc Stock (SVRA) Latest News
Savara Advances MOLBREEVI Toward Approval as Financing Boost Extends Cash Runway - MSN
Securities Lawsuit Alert: Savara Inc. (SVRA)Contact Levi & Korsinsky Before November 7, 2025 - The National Law Review
Levi & Korsinsky Invites Investors to SueWallSt After Savara Inc. Stock Collapse - The National Law Review
Savara Inc. (NASDAQ:SVRA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Savara Announces Participation in Upcoming December 2025 Investor Healthcare Conferences - BioSpace
Applying sector rotation models to Savara Inc.2025 Pullback Review & Accurate Intraday Trading Signals - newser.com
Savara Announces Participation in Upcoming Investor Healthcare Conferences - Bluefield Daily Telegraph
Global NTM Infections Pipeline Poised for Growth as Breakthrough Therapies Advance Toward Late-Stage Development, states DelveInsight - The Globe and Mail
Savara (NASDAQ:SVRA) Shares Up 7.3%Still a Buy? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Savara Inc. (SVRA) And Encourages Stockholders to Connect - ACCESS Newswire
Adversity is less terrifying than hope: Savara Inc (SVRA) - Setenews
How Savara Inc. stock compares to industry benchmarksOptions Play & Weekly Breakout Watchlists - newser.com
Savara (NASDAQ:SVRA) Reaches New 52-Week HighTime to Buy? - MarketBeat
Pattern recognition hints at Savara Inc. upsideWeekly Trade Review & Long-Term Capital Growth Ideas - newser.com
Investigation announced for Long-Term Investors in shares of Savara Inc. (NASDAQ: SVRA) - openPR.com
Will Savara Inc. stock continue dividend increasesWeekly Profit Report & Free Low Drawdown Momentum Trade Ideas - newser.com
What makes Markel Group Inc. stock price move sharply - newser.com
Visual analytics tools that track Savara Inc. performance2025 Price Action Summary & Fast Entry and Exit Trade Plans - newser.com
Full technical analysis of Savara Inc. stock2025 Risk Factors & Weekly Setup with ROI Potential - newser.com
Is Savara Inc. stock trading at a premium valuationIPO Watch & Free Technical Pattern Based Buy Signals - newser.com
Is Savara Inc. (YB4P) stock in buy zone after pullbackPortfolio Update Report & Advanced Swing Trade Entry Alerts - newser.com
Volatility clustering patterns for Savara Inc.Market Volume Report & Detailed Earnings Play Strategies - newser.com
Savara Inc stock hits 52-week high at 4.51 USD By Investing.com - Investing.com Nigeria
Savara Inc. stock momentum explainedWeekly Trading Summary & Daily Profit Focused Stock Screening - newser.com
Savara Inc stock hits 52-week high at 4.51 USD - Investing.com
Short interest data insights for Savara Inc.Trade Volume Summary & Fast Entry High Yield Tips - newser.com
Savara Inc. $SVRA Shares Sold by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
Multi asset correlation models including Savara Inc.Earnings Risk Summary & Weekly Return Optimization Plans - newser.com
Will Savara Inc. (YB4P) stock boost dividends furtherWeekly Risk Summary & Long-Term Capital Growth Ideas - newser.com
Is Savara Inc. stock attractive for income investorsPortfolio Performance Summary & Weekly Watchlist of Top Performers - newser.com
Savara Inc. (SVRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
HC Wainwright Has Positive Outlook of Savara FY2029 Earnings - MarketBeat
Savara Inc. Reports Q3 2025 Financial Results - TipRanks
[Form 4] Savara Inc Insider Trading Activity - Stock Titan
Lifesci Capital Analysts Raise Earnings Estimates for Savara - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Savara Inc. (SVRA) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Is Savara Inc. (YB4P) stock supported by free cash flowTreasury Yields & Fast Entry Momentum Trade Alerts - newser.com
What Fibonacci levels say about Savara Inc. rebound2025 Momentum Check & Fast Moving Stock Watchlists - newser.com
2025-11-16 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Savara Inc. (SVRA) and Encourages Stockholders to Learn More About the Investigation | NDAQ:SVRA | Press Release - Stockhouse
Savara Stock: A High-Risk Opportunity (NASDAQ:SVRA) - Seeking Alpha
Oppenheimer Reaffirms Their Buy Rating on Savara (SVRA) - The Globe and Mail
Why Savara Inc. stock could outperform in 2025Market Movement Recap & Free Technical Pattern Based Buy Signals - newser.com
Savara Inc Stock (SVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Savara Inc Stock (SVRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hawkins Richard J | Director |
Jun 20 '25 |
Buy |
2.04 |
48,225 |
98,572 |
115,466 |
| McCracken Joseph S | Director |
May 29 '25 |
Buy |
2.08 |
10,000 |
20,825 |
260,837 |
| RAMSAY DAVID A | Director |
Mar 31 '25 |
Buy |
2.77 |
150,000 |
416,250 |
2,513,642 |
| Lowrance David L | Chief Financial Officer |
Dec 16 '24 |
Sale |
3.33 |
25,000 |
83,278 |
381,005 |
| Pauls Matthew | CHIEF EXECUTIVE OFFICER |
Dec 16 '24 |
Sale |
3.31 |
54,702 |
180,828 |
1,536,379 |
| Hawkins Richard J | Director |
Dec 16 '24 |
Sale |
3.32 |
8,000 |
26,569 |
67,241 |
0.36%
1.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):